Publications

Detailed Information

The effect of hospice consultation on aggressive treatment of lung cancer

Cited 16 time in Web of Science Cited 17 time in Scopus
Authors

Yoo, Shin Hye; Keam, Bhumsuk; Kim, Miso; Kim, Tae Min; Kim, Dong-Wan; Heo, Dae Seog

Issue Date
2018-07
Publisher
대한암학회
Citation
Cancer Research and Treatment, Vol.50 No.3, pp.720-728
Abstract
Purpose The aims of this study were to investigate trends of aggressive treatment of non-small cell lung cancer (NSCLC) patients at the end-of-life (EOL) during the recent 5 years and examine the relationship between hospice consultation (HC) and aggressive care. Materials and Methods The medical records of 789 patients with stage IIIB-IV NSCLC at Seoul National University Hospital (SNUH) who received palliative chemotherapy and died from 2010 to 2014 were retrospectively reviewed. Indicators of aggressive treatment were evaluated, and the association of HC with these indicators was analyzed. Results During the last 5 years, the frequency of HC increased from 26.7% to 43.6%. The time interval from last chemotherapy to death increased, and the proportion of patients who received palliative chemotherapy, visited an emergency room, were admitted to intensive care unit, during the last month of life, and died in SNUH significantly decreased over time. Referral to HC was significantly associated with lower intensive care unit admission rates, lower out-of-hospital death rates, and less use of the chemotherapy within 1 month prior to death. Overall survival did not differ by HC. Conclusion The pattern of cancer care near the EOL has become less aggressive when HC was provided. The positive association of HC with better EOL care suggests that providing HC at the optimal time might help to avoid futile aggressive treatment.
ISSN
1598-2998
URI
https://hdl.handle.net/10371/165237
DOI
https://doi.org/10.4143/crt.2017.169
Files in This Item:
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share